{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T03:11:55Z","timestamp":1794107515262,"version":"4.8.0"},"reference-count":210,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T00:00:00Z","timestamp":1631836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T00:00:00Z","timestamp":1631836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1038\/s41573-021-00284-4","type":"journal-article","created":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T06:04:13Z","timestamp":1631858653000},"page":"60-78","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":532,"title":["Emerging therapeutic opportunities for integrin inhibitors"],"prefix":"10.1038","volume":"21","author":[{"given":"R. J.","family":"Slack","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4859-8246","authenticated-orcid":false,"given":"S. J. F.","family":"Macdonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8910-6033","authenticated-orcid":false,"given":"J. A.","family":"Roper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7929-2119","authenticated-orcid":false,"given":"R. G.","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3172-2511","authenticated-orcid":false,"given":"R. J. D.","family":"Hatley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,17]]},"reference":[{"key":"284_CR1","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/0092-8674(87)90233-9","volume":"48","author":"RO Hynes","year":"1987","unstructured":"Hynes, R. O. Integrins: a family of cell surface receptors. Cell 48, 549\u2013554 (1987).","journal-title":"Cell"},{"key":"284_CR2","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0092-8674(02)00971-6","volume":"110","author":"RO Hynes","year":"2002","unstructured":"Hynes, R. O. Integrins: bidirectional, allosteric signaling machines. Cell 110, 673\u2013687 (2002).","journal-title":"Cell"},{"key":"284_CR3","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1681\/ASN.V781091","volume":"7","author":"RJ Faull","year":"1996","unstructured":"Faull, R. J. & Ginsberg, M. H. Inside-out signaling through integrins. J. Am. Soc. Nephrol. 7, 1091\u20131097 (1996).","journal-title":"J. Am. Soc. Nephrol."},{"key":"284_CR4","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1182\/blood-2007-03-080077","volume":"110","author":"J Zhu","year":"2007","unstructured":"Zhu, J. et al. Requirement of alpha and beta subunit transmembrane helix separation for integrin outside-in signaling. Blood 110, 2475\u20132483 (2007).","journal-title":"Blood"},{"key":"284_CR5","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/nrm2871","volume":"11","author":"SJ Shattil","year":"2010","unstructured":"Shattil, S. J., Kim, C. & Ginsberg, M. H. The final steps of integrin activation: the end game. Nat. Rev. Mol. Cell. Biol. 11, 288\u2013300 (2010).","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"284_CR6","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1242\/jcs.190991","volume":"130","author":"B Klapholz","year":"2017","unstructured":"Klapholz, B. & Brown, N. H. Talin \u2014 the master of integrin adhesions. J. Cell Sci. 130, 2435\u20132446 (2017).","journal-title":"J. Cell Sci."},{"key":"284_CR7","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/nrm3624","volume":"14","author":"DA Calderwood","year":"2013","unstructured":"Calderwood, D. A., Campbell, I. D. & Critchley, D. R. Talins and kindlins: partners in integrin-mediated adhesion. Nat. Rev. Mol. Cell Biol. 14, 503\u2013517 (2013).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"284_CR8","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1242\/jcs.03098","volume":"119","author":"JD Humphries","year":"2006","unstructured":"Humphries, J. D., Byron, A. & Humphries, M. J. Integrin ligands at a glance. J. Cell Sci. 119, 3901\u20133903 (2006).","journal-title":"J. Cell Sci."},{"key":"284_CR9","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1146\/annurev.cellbio.12.1.697","volume":"12","author":"E Ruoslahti","year":"1996","unstructured":"Ruoslahti, E. RGD and other recognition sequences for integrins. Annu. Rev. Cell Dev. Biol. 12, 697\u2013715 (1996).","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"284_CR10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0079-6336(02)80008-0","volume":"37","author":"DE Gullberg","year":"2002","unstructured":"Gullberg, D. E. & Lundgren-Akerlund, E. Collagen-binding I domain integrins \u2014 what do they do? Prog. Histochem. Cytochem. 37, 3\u201354 (2002).","journal-title":"Prog. Histochem. Cytochem."},{"key":"284_CR11","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4161\/cam.22826","volume":"7","author":"M Aumailley","year":"2013","unstructured":"Aumailley, M. The laminin family. Cell Adh. Migr. 7, 48\u201355 (2013).","journal-title":"Cell Adh. Migr."},{"key":"284_CR12","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1242\/jcs.188672","volume":"129","author":"C Zeltz","year":"2016","unstructured":"Zeltz, C. & Gullberg, D. The integrin-collagen connection \u2014 a glue for tissue repair? J. Cell Sci. 129, 653\u2013664 (2016).","journal-title":"J. Cell Sci."},{"key":"284_CR13","doi-asserted-by":"crossref","DOI":"10.1017\/S1462399409001355","volume":"12","author":"CS Stipp","year":"2010","unstructured":"Stipp, C. S. Laminin-binding integrins and their tetraspanin partners as potential antimetastatic targets. Expert Rev. Mol. Med. 12, e3 (2010).","journal-title":"Expert Rev. Mol. Med."},{"key":"284_CR14","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/17460441.2020.1819234","volume":"16","author":"D Cox","year":"2020","unstructured":"Cox, D. How not to discover a drug \u2014 integrins. Expert Opin. Drug Discov. 16, 197\u2013211 (2020).","journal-title":"Expert Opin. Drug Discov."},{"key":"284_CR15","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.2174\/1381612043384682","volume":"10","author":"JF Fullard","year":"2004","unstructured":"Fullard, J. F. The role of the platelet glycoprotein IIb\/IIIa in thrombosis and haemostasis. Curr. Pharm. Des. 10, 1567\u20131576 (2004).","journal-title":"Curr. Pharm. Des."},{"key":"284_CR16","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jtos.2016.01.001","volume":"14","author":"VL Perez","year":"2016","unstructured":"Perez, V. L., Pflugfelder, S. C., Zhang, S., Shojaei, A. & Haque, R. Lifitegrast, a novel integrin antagonist for treatment of dry eye disease. Ocul. Surf. 14, 207\u2013215 (2016).","journal-title":"Ocul. Surf."},{"key":"284_CR17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.pharmthera.2014.11.008","volume":"147","author":"I Mitroulis","year":"2015","unstructured":"Mitroulis, I. et al. Leukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory disease. Pharmacol. Ther. 147, 123\u2013135 (2015).","journal-title":"Pharmacol. Ther."},{"key":"284_CR18","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1053\/gast.2001.26260","volume":"121","author":"FH Gordon","year":"2001","unstructured":"Gordon, F. H. et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn\u2019s disease. Gastroenterology 121, 268\u2013274 (2001).","journal-title":"Gastroenterology"},{"key":"284_CR19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3233\/HAB-1997-8102","volume":"8","author":"OJ L\u00e9ger","year":"1997","unstructured":"L\u00e9ger, O. J. et al. Humanization of a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis. Hum. Antibodies 8, 3\u201316 (1997).","journal-title":"Hum. Antibodies"},{"key":"284_CR20","unstructured":"Biogen reports record revenues for both the full year and fourth quarter of 2017, $12.3 billion and $3.3 billion, respectively. Businesswire https:\/\/www.businesswire.com\/news\/home\/20180125005353\/en\/Biogen-Reports-Record-Revenues-Full-Year-Fourth (2018)."},{"key":"284_CR21","unstructured":"Tong, A. Takeda reports second PhIII win for subcutaneous Entyvio as regulators review expanded use. Endpoints https:\/\/endpts.com\/takeda-reports-second-phiii-win-for-subcutaneous-entyvio-as-regulators-review-expanded-use\/ (2019)."},{"key":"284_CR22","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3390\/cancers9090110","volume":"9","author":"S Raab-Westphal","year":"2017","unstructured":"Raab-Westphal, S., Marshall, J. F. & Goodman, S. L. Integrins as therapeutic targets: successes and cancers. Cancers 9, 110 (2017).","journal-title":"Cancers"},{"key":"284_CR23","volume":"10","author":"B Xie","year":"2020","unstructured":"Xie, B. et al. Idiopathic pulmonary fibrosis registry china study (PORTRAY): protocol for a prospective, multicentre registry study. BMJ Open 10, e036809 (2020).","journal-title":"BMJ Open"},{"key":"284_CR24","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2468-1253(19)30419-4","volume":"5","author":"K Abeysekera","year":"2020","unstructured":"Abeysekera, K. et al. Prevalence of steatosis and fibrosis in young adults in the UK: a population-based study. Lancet Gastroenterol. Hepatol. 5, 295\u2013305 (2020).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"284_CR25","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/sj.onc.1202172","volume":"17","author":"CC Kumar","year":"1998","unstructured":"Kumar, C. C. Signaling by integrin receptors. Oncogene 17, 1365\u20131373 (1998).","journal-title":"Oncogene"},{"key":"284_CR26","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.tips.2012.04.002","volume":"33","author":"SL Goodman","year":"2012","unstructured":"Goodman, S. L. & Picard, M. Integrins as therapeutic targets. Trends Pharmacol. Sci. 33, 405\u2013412 (2012).","journal-title":"Trends Pharmacol. Sci."},{"key":"284_CR27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrc2748","volume":"10","author":"JS Desgrosellier","year":"2010","unstructured":"Desgrosellier, J. S. & Cheresh, D. A. Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 10, 9\u201322 (2010).","journal-title":"Nat. Rev. Cancer"},{"key":"284_CR28","doi-asserted-by":"crossref","first-page":"9764","DOI":"10.1073\/pnas.93.18.9764","volume":"93","author":"M Friedlander","year":"1996","unstructured":"Friedlander, M. et al. Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. Proc. Natl Acad. Sci. USA 93, 9764\u20139769 (1996).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"284_CR29","doi-asserted-by":"crossref","first-page":"ii96","DOI":"10.1136\/ard.61.suppl_2.ii96","volume":"61","author":"RL Wilder","year":"2002","unstructured":"Wilder, R. L. Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases. Ann. Rheum. Dis. 61, ii96\u2013ii99 (2002).","journal-title":"Ann. Rheum. Dis."},{"key":"284_CR30","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00774-007-0773-9","volume":"25","author":"I Nakamura","year":"2007","unstructured":"Nakamura, I., Duong, L. T., Rodan, S. B. & Rodan, G. A. Involvement of alpha(v)beta3 integrins in osteoclast function. J. Bone Miner. Metab. 25, 337\u2013344 (2007).","journal-title":"J. Bone Miner. Metab."},{"key":"284_CR31","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/sj.bjc.6601576","volume":"90","author":"H Jin","year":"2004","unstructured":"Jin, H. & Varner, J. Integrins: roles in cancer development and as treatment targets. Br. J. Cancer 90, 561\u2013565 (2004).","journal-title":"Br. J. Cancer"},{"key":"284_CR32","doi-asserted-by":"publisher","unstructured":"Van Hove, I. et al. Targeting RGD-binding integrins as an integrative therapy for diabetic retinopathy and neovascular age-related macular degeneration. Prog. Retin. Eye Res. https:\/\/doi.org\/10.1016\/j.preteyeres.2021.100966 (2021).","DOI":"10.1016\/j.preteyeres.2021.100966"},{"key":"284_CR33","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1080\/13543784.2020.1795639","volume":"29","author":"AD Bhatwadekar","year":"2020","unstructured":"Bhatwadekar, A. D., Kansara, V., Luo, Q. & Ciulla, T. Anti-integrin therapy for retinovascular diseases. Expert Opin. Investig. Drugs 29, 935\u2013945 (2020).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"284_CR34","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1124\/jpet.118.248427","volume":"366","author":"BC Askew","year":"2018","unstructured":"Askew, B. C., Furuya, T. & Edwards, D. S. Ocular distribution and pharmacodynamics of SF0166, a topically administered \u03b1v\u03b23 integrin antagonist, for the treatment of retinal diseases. J. Pharmacol. Exp. Ther. 366, 244\u2013250 (2018).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"284_CR35","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1001\/archophthalmol.2009.265","volume":"127","author":"G Zahn","year":"2009","unstructured":"Zahn, G. et al. Preclinical evaluation of the novel small-molecule integrin alpha5beta1 inhibitor JSM6427 in monkey and rabbit models of choroidal neovascularization. Arch. Ophthalmol. 127, 1329\u20131335 (2009).","journal-title":"Arch. Ophthalmol."},{"key":"284_CR36","doi-asserted-by":"crossref","first-page":"eaai8030","DOI":"10.1126\/scitranslmed.aai8030","volume":"9","author":"R Silva","year":"2017","unstructured":"Silva, R. et al. Tyrosine kinase blocking collagen IV-derived peptide suppresses ocular neovascularization and vascular leakage. Sci. Transl. Med. 9, eaai8030 (2017).","journal-title":"Sci. Transl. Med."},{"key":"284_CR37","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.122043","volume":"4","author":"AC Mirando","year":"2019","unstructured":"Mirando, A. C. et al. A collagen IV-derived peptide disrupts \u03b15\u03b21 integrin and potentiates Ang2\/Tie2 signaling. JCI Insight 4, e122043 (2019).","journal-title":"JCI Insight"},{"key":"284_CR38","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3390\/cancers11070978","volume":"11","author":"B Alday-Parejo","year":"2019","unstructured":"Alday-Parejo, B., Stupp, R. & R\u00fcegg, C. Are integrins still practicable targets for anti-cancer therapy? Cancers 11, 978 (2019).","journal-title":"Cancers"},{"key":"284_CR39","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S1470-2045(14)70379-1","volume":"15","author":"R Stupp","year":"2014","unstructured":"Stupp, R. et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 15, 1100\u20131108 (2014).","journal-title":"Lancet Oncol."},{"key":"284_CR40","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/neuonc\/nov018","volume":"17","author":"WP Mason","year":"2015","unstructured":"Mason, W. P. End of the road: confounding results of the CORE trial terminate the arduous journey of cilengitide for glioblastoma. Neuro. Oncol. 17, 634\u2013635 (2015).","journal-title":"Neuro. Oncol."},{"key":"284_CR41","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1002\/cncr.24821","volume":"116","author":"P Hersey","year":"2010","unstructured":"Hersey, P. et al. A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or \u2212 dacarbazine in patients with stage IV metastatic melanoma. Cancer 116, 1526\u20131534 (2010).","journal-title":"Cancer"},{"key":"284_CR42","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s10637-015-0320-9","volume":"34","author":"GA Cirkel","year":"2016","unstructured":"Cirkel, G. A. et al. A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies. Invest. New Drugs 34, 184\u2013192 (2016).","journal-title":"Invest. New Drugs"},{"key":"284_CR43","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1124\/pr.117.014944","volume":"70","author":"A Shergalis","year":"2018","unstructured":"Shergalis, A., Bankhead, A. III, Luesakul, U., Muangsin, N. & Neamati, N. Current challenges and opportunities in treating glioblastoma. Pharmacol. Rev. 70, 412\u2013445 (2018).","journal-title":"Pharmacol. Rev."},{"key":"284_CR44","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrrheum.2011.77","volume":"7","author":"AG Costa","year":"2011","unstructured":"Costa, A. G., Cusano, N. E., Silva, B. C., Cremers, S. & Bilezikian, J. P. Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis. Nat. Rev. Rheumatol. 7, 447\u2013456 (2011).","journal-title":"Nat. Rev. Rheumatol."},{"key":"284_CR45","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/ICU.0000000000000657","volume":"31","author":"MJ Ammar","year":"2020","unstructured":"Ammar, M. J., Hsu, J., Chiang, A., Ho, A. C. & Regillo, C. D. Age-related macular degeneration therapy: a review. Curr. Opin. Ophthalmol. 31, 215\u2013221 (2020).","journal-title":"Curr. Opin. Ophthalmol."},{"key":"284_CR46","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1038\/nm.4431","volume":"23","author":"N Hosen","year":"2017","unstructured":"Hosen, N. et al. The activated conformation of integrin \u03b27 is a novel multiple myeloma-specific target for CAR T cell therapy. Nat. Med. 23, 1436\u20131443 (2017).","journal-title":"Nat. Med."},{"key":"284_CR47","doi-asserted-by":"crossref","DOI":"10.1002\/acg2.11","volume":"1","author":"L Wallstabe","year":"2018","unstructured":"Wallstabe, L. et al. CAR T cells targeting \u03b1v\u03b23 integrin are effective against advanced cancer in preclinical models. Adv. Cell Gene Ther. 1, e11 (2018).","journal-title":"Adv. Cell Gene Ther."},{"key":"284_CR48","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ymthe.2016.10.012","volume":"25","author":"LM Whilding","year":"2017","unstructured":"Whilding, L. M. et al. Targeting of aberrant \u03b1v\u03b26 integrin expression in solid tumors using chimeric antigen receptor-engineered T cells. Mol. Ther. 25, 259\u2013273 (2017).","journal-title":"Mol. Ther."},{"key":"284_CR49","doi-asserted-by":"crossref","first-page":"32314","DOI":"10.1074\/jbc.M113.501668","volume":"288","author":"Y Yu","year":"2013","unstructured":"Yu, Y., Sch\u00fcrpf, T. & Springer, T. A. How natalizumab binds and antagonizes \u03b14 integrins. J. Biol. Chem. 288, 32314\u201332325 (2013).","journal-title":"J. Biol. Chem."},{"key":"284_CR50","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1146\/annurev.immunol.25.022106.141618","volume":"25","author":"BH Luo","year":"2007","unstructured":"Luo, B. H., Carman, C. V. & Springer, T. A. Structural basis of integrin regulation and signaling. Annu. Rev. Immunol. 25, 619\u2013647 (2007).","journal-title":"Annu. Rev. Immunol."},{"key":"284_CR51","doi-asserted-by":"crossref","first-page":"5275","DOI":"10.1158\/0008-5472.CAN-07-0318","volume":"67","author":"AG Ramsay","year":"2007","unstructured":"Ramsay, A. G. et al. HS1-associated protein X-1 regulates carcinoma cell migration and invasion via clathrin-mediated endocytosis of integrin alphavbeta6. Cancer Res. 67, 5275\u20135284 (2007).","journal-title":"Cancer Res."},{"key":"284_CR52","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1161\/01.ATV.0000255307.65939.59","volume":"27","author":"N Bassler","year":"2007","unstructured":"Bassler, N. et al. A mechanistic model for paradoxical platelet activation by ligand-mimetic alphaIIb beta3 (GPIIb\/IIIa) antagonists. Arterioscler. Thromb. Vasc. Biol. 27, e9\u2013e15 (2007).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"284_CR53","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/j.1538-7836.2009.03360.x","volume":"7","author":"RH Aster","year":"2009","unstructured":"Aster, R. H., Curtis, B. R., McFarland, J. G. & Bougie, D. W. Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management. J. Thromb. Haemost. 7, 911\u2013918 (2009).","journal-title":"J. Thromb. Haemost."},{"key":"284_CR54","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrd.2015.10","volume":"15","author":"K Ley","year":"2016","unstructured":"Ley, K., Rivera-Nieves, J., Sandborn, W. J. & Shattil, S. Integrin-based therapeutics: biological basis, clinical use and new drugs. Nat. Rev. Drug Discov. 15, 173\u2013183 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"284_CR55","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1161\/01.CIR.102.2.149","volume":"102","author":"CP Cannon","year":"2000","unstructured":"Cannon, C. P. et al. Oral glycoprotein IIb\/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation 102, 149\u2013156 (2000).","journal-title":"Circulation"},{"key":"284_CR56","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/nm.1941","volume":"15","author":"AR Reynolds","year":"2009","unstructured":"Reynolds, A. R. et al. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat. Med. 15, 392\u2013400 (2009).","journal-title":"Nat. Med."},{"key":"284_CR57","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.ccr.2009.04.005","volume":"15","author":"SM Weis","year":"2009","unstructured":"Weis, S. M., Stupack, D. G. & Cheresh, D. A. Agonizing integrin antagonists? Cancer Cell 15, 359\u2013361 (2009).","journal-title":"Cancer Cell"},{"key":"284_CR58","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1124\/jpet.111.179309","volume":"338","author":"FJ Ehlert","year":"2011","unstructured":"Ehlert, F. J., Suga, H. & Griffin, M. T. Analysis of agonism and inverse agonism in functional assays with constitutive activity: estimation of orthosteric ligand affinity constants for active and inactive receptor states. J. Pharmacol. Exp. Ther. 338, 671\u2013686 (2011).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"284_CR59","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ccell.2014.10.015","volume":"27","author":"PP Wong","year":"2015","unstructured":"Wong, P. P. et al. Dual-action combination therapy enhances angiogenesis while reducing tumor growth and spread. Cancer Cell 27, 123\u2013137 (2015).","journal-title":"Cancer Cell"},{"key":"284_CR60","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1021\/acsptsci.9b00041","volume":"2","author":"J Li","year":"2019","unstructured":"Li, J. et al. Novel pure \u03b1V\u03b23 integrin antagonists that do not induce receptor extension, prime the receptor, or enhance angiogenesis at low concentrations. ACS Pharmacol. Transl. Sci. 2, 387\u2013401 (2019).","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"284_CR61","doi-asserted-by":"crossref","first-page":"5050","DOI":"10.1182\/blood-2010-04-281154","volume":"116","author":"J Zhu","year":"2010","unstructured":"Zhu, J. et al. Closed headpiece of integrin \u03b1IIb\u03b23 and its complex with an \u03b1IIb\u03b23-specific antagonist that does not induce opening. Blood 116, 5050\u20135059 (2010).","journal-title":"Blood"},{"key":"284_CR62","first-page":"125ra32","volume":"4","author":"J Zhu","year":"2012","unstructured":"Zhu, J. et al. Structure-guided design of a high-affinity platelet integrin \u03b1IIb\u03b23 receptor antagonist that disrupts Mg\u00b2+ binding to the MIDAS. Sci. Transl. Med. 4, 125ra32 (2012).","journal-title":"Sci. Transl. Med."},{"key":"284_CR63","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1161\/ATVBAHA.114.303724","volume":"34","author":"J Li","year":"2014","unstructured":"Li, J. et al. RUC-4: a novel \u03b1IIb\u03b23 antagonist for prehospital therapy of myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 34, 2321\u20132329 (2014).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"284_CR64","unstructured":"CeleCor initiates CELEBRATE, a pivotal clinical trial of subcutaneously administered Zalunfiban (RUC-4) in STEMI patients treated in ambulances. https:\/\/www.celecor.com\/blog\/https\/wwwcelecorcom (2021)."},{"key":"284_CR65","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.016552","volume":"9","author":"DJ Kereiakes","year":"2020","unstructured":"Kereiakes, D. J. et al. First human use of RUC-4: a nonactivating second-generation small-molecule platelet glycoprotein IIb\/IIIa (integrin \u03b1IIb\u03b23) inhibitor designed for subcutaneous point-of-care treatment of ST-segment-elevation myocardial infarction. J. Am. Heart Assoc. 9, e016552 (2020).","journal-title":"J. Am. Heart Assoc."},{"key":"284_CR66","unstructured":"Morphic Therapeutic. MINT platform and strategy. https:\/\/morphictx.com\/our-technology\/mint-platform-and-strategy (2018)."},{"key":"284_CR67","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nsmb.2797","volume":"21","author":"JF Van Agthoven","year":"2014","unstructured":"Van Agthoven, J. F. et al. Structural basis for pure antagonism of integrin \u03b1V\u03b23 by a high-affinity form of fibronectin. Nat. Struct. Mol. Biol. 21, 383\u2013388 (2014).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"284_CR68","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-13928-2","volume":"11","author":"BD Adair","year":"2020","unstructured":"Adair, B. D. et al. Structure-guided design of pure orthosteric inhibitors of \u03b1IIb\u03b23 that prevent thrombosis but preserve hemostasis. Nat. Commun. 11, 398 (2020).","journal-title":"Nat. Commun."},{"key":"284_CR69","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1111\/jth.13803","volume":"15","author":"YJ Kuo","year":"2017","unstructured":"Kuo, Y. J., Chen, Y. R., Hsu, C. C., Peng, H. C. & Huang, T. F. An \u03b1IIb\u03b23 antagonist prevents thrombosis without causing Fc receptor \u03b3-chain IIa-mediated thrombocytopenia. J. Thromb. Haemost. 15, 2230\u20132244 (2017).","journal-title":"J. Thromb. Haemost."},{"key":"284_CR70","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3389\/fonc.2013.00222","volume":"3","author":"UK Marelli","year":"2013","unstructured":"Marelli, U. K., Rechenmacher, F., Sobahi, T. R., Mas-Moruno, C. & Kessler, H. Tumor targeting via integrin ligands. Front. Oncol. 3, 222 (2013).","journal-title":"Front. Oncol."},{"key":"284_CR71","volume":"11","author":"AE John","year":"2020","unstructured":"John, A. E. et al. Translational pharmacology of an inhaled small molecule \u03b1v\u03b26 integrin inhibitor for idiopathic pulmonary fibrosis. Nat. Commun. 11, 4659 (2020).","journal-title":"Nat. Commun."},{"key":"284_CR72","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1002\/anie.201707948","volume":"57","author":"R Hatley","year":"2018","unstructured":"Hatley, R. et al. An \u03b1v-RGD integrin inhibitor toolbox: drug discovery insight, challenges and opportunities. Angew. Chem. Int. Ed. Engl. 57, 3298\u20133321 (2018).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"284_CR73","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/nchembio.1867","volume":"11","author":"CH Arrowsmith","year":"2015","unstructured":"Arrowsmith, C. H. et al. The promise and peril of chemical probes. Nat. Chem. Biol. 11, 536\u2013541 (2015).","journal-title":"Nat. Chem. Biol."},{"key":"284_CR74","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ejphar.2018.10.045","volume":"842","author":"AL Wilkinson","year":"2019","unstructured":"Wilkinson, A. L., Barrett, J. W. & Slack, R. J. Pharmacological characterisation of a tool \u03b1v\u03b21 integrin small molecule RGD-mimetic inhibitor. Eur. J. Pharmacol. 842, 239\u2013247 (2019).","journal-title":"Eur. J. Pharmacol."},{"key":"284_CR75","first-page":"288ra79","volume":"7","author":"NI Reed","year":"2015","unstructured":"Reed, N. I. et al. The \u03b1v\u03b21 integrin plays a critical in vivo role in tissue fibrosis. Sci. Transl. Med. 7, 288ra79 (2015).","journal-title":"Sci. Transl. Med."},{"key":"284_CR76","doi-asserted-by":"crossref","first-page":"L439","DOI":"10.1152\/ajplung.00258.2010","volume":"299","author":"CJ Scotton","year":"2010","unstructured":"Scotton, C. J. & Chambers, R. C. Bleomycin revisited: towards a more representative model of IPF? Am. J. Physiol. Lung Cell Mol. Physiol. 299, L439\u2013L441 (2010).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"284_CR77","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1164\/rccm.200706-805OC","volume":"177","author":"GS Horan","year":"2008","unstructured":"Horan, G. S. et al. Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation. Am. J. Respir. Crit. Care Med. 177, 56\u201365 (2008).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"284_CR78","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1183\/09031936.00210414","volume":"46","author":"G Saini","year":"2015","unstructured":"Saini, G. et al. \u03b1v\u03b26 integrin may be a potential prognostic biomarker in interstitial lung disease. Eur. Respir. J. 46, 486\u2013494 (2015).","journal-title":"Eur. Respir. J."},{"key":"284_CR79","doi-asserted-by":"crossref","first-page":"17875","DOI":"10.1074\/jbc.M312103200","volume":"279","author":"PH Weinreb","year":"2004","unstructured":"Weinreb, P. H. et al. Function-blocking integrin alphavbeta6 monoclonal antibodies: distinct ligand-mimetic and nonligand-mimetic classes. J. Biol. Chem. 279, 17875\u201317887 (2004).","journal-title":"J. Biol. Chem."},{"key":"284_CR80","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1101\/gad.9.15.1883","volume":"9","author":"LE Stephens","year":"1995","unstructured":"Stephens, L. E. et al. Deletion of beta 1 integrins in mice results in inner cell mass failure and peri-implantation lethality. Genes Dev. 9, 1883\u20131895 (1995).","journal-title":"Genes Dev."},{"key":"284_CR81","volume":"11","author":"J Zhang","year":"2021","unstructured":"Zhang, J. et al. Discovery of a new class of integrin antibodies for fibrosis. Sci. Rep. 11, 2118 (2021).","journal-title":"Sci. Rep."},{"key":"284_CR82","first-page":"213","volume":"119","author":"KK Kim","year":"2009","unstructured":"Kim, K. K. et al. Epithelial cell alpha3beta1 integrin links beta-catenin and Smad signaling to promote myofibroblast formation and pulmonary fibrosis. J. Clin. Invest. 119, 213\u2013224 (2009).","journal-title":"J. Clin. Invest."},{"key":"284_CR83","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0006-2952(00)00491-3","volume":"60","author":"Q Wang","year":"2000","unstructured":"Wang, Q. et al. Effect of antibody against integrin alpha4 on bleomycin-induced pulmonary fibrosis in mice. Biochem. Pharmacol. 60, 1949\u20131958 (2000).","journal-title":"Biochem. Pharmacol."},{"key":"284_CR84","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3109\/15419061.2013.876012","volume":"21","author":"G Volkert","year":"2014","unstructured":"Volkert, G. et al. Contribution of the \u03b18 integrin chain to the expression of extracellular matrix components. Cell Commun. Adhes. 21, 89\u201398 (2014).","journal-title":"Cell Commun. Adhes."},{"key":"284_CR85","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1172\/JCI45589","volume":"121","author":"H Kitamura","year":"2011","unstructured":"Kitamura, H. et al. Mouse and human lung fibroblasts regulate dendritic cell trafficking, airway inflammation, and fibrosis through integrin \u03b1v\u03b28-mediated activation of TGF-\u03b2. J. Clin. Invest. 121, 2863\u20132875 (2011).","journal-title":"J. Clin. Invest."},{"key":"284_CR86","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jhep.2007.11.021","volume":"48","author":"Y Popov","year":"2008","unstructured":"Popov, Y. et al. Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies. J. Hepatol. 48, 453\u2013464 (2008).","journal-title":"J. Hepatol."},{"key":"284_CR87","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1038\/nm.3282","volume":"19","author":"NC Henderson","year":"2013","unstructured":"Henderson, N. C. et al. Targeting of \u03b1v integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat. Med. 19, 1617\u20131624 (2013).","journal-title":"Nat. Med."},{"key":"284_CR88","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/hep.21849","volume":"46","author":"B Wang","year":"2007","unstructured":"Wang, B. et al. Role of alphavbeta6 integrin in acute biliary fibrosis. Hepatology 46, 1404\u20131412 (2007).","journal-title":"Hepatology"},{"key":"284_CR89","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/hep4.1298","volume":"3","author":"B Ulmasov","year":"2018","unstructured":"Ulmasov, B. et al. An inhibitor of arginine-glycine-aspartate-binding integrins reverses fibrosis in a mouse model of nonalcoholic steatohepatitis. Hepatol. Commun. 3, 246\u2013261 (2018).","journal-title":"Hepatol. Commun."},{"key":"284_CR90","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1053\/j.ackd.2016.11.002","volume":"24","author":"BM Klinkhammer","year":"2017","unstructured":"Klinkhammer, B. M., Goldschmeding, R., Floege, J. & Boor, P. Treatment of renal fibrosis-turning challenges into opportunities. Adv. Chronic Kidney Dis. 24, 117\u2013129 (2017).","journal-title":"Adv. Chronic Kidney Dis."},{"key":"284_CR91","doi-asserted-by":"crossref","first-page":"110","DOI":"10.2353\/ajpath.2007.060158","volume":"170","author":"K Hahm","year":"2007","unstructured":"Hahm, K. et al. Alphav beta6 integrin regulates renal fibrosis and inflammation in Alport mouse. Am. J. Pathol. 170, 110\u2013125 (2007).","journal-title":"Am. J. Pathol."},{"key":"284_CR92","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1681\/ASN.2015050585","volume":"28","author":"Y Chang","year":"2017","unstructured":"Chang, Y. et al. Pharmacologic blockade of \u03b1v\u03b21 integrin ameliorates renal failure and fibrosis in vivo. J. Am. Soc. Nephrol. 28, 1998\u20132005 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"284_CR93","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S0002-9440(10)63486-4","volume":"163","author":"LJ Ma","year":"2003","unstructured":"Ma, L. J. et al. Transforming growth factor-beta-dependent and -independent pathways of induction of tubulointerstitial fibrosis in beta6(\u2212\/\u2212) mice. Am. J. Pathol. 163, 1261\u20131273 (2003).","journal-title":"Am. J. Pathol."},{"key":"284_CR94","unstructured":"Cox, J. M. et al. Composition and methods for treating chronic kidney disease. US 20190307735 (2019)."},{"key":"284_CR95","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.354","volume":"5","author":"X Zhou","year":"2017","unstructured":"Zhou, X. et al. An integrin antagonist (MK-0429) decreases proteinuria and renal fibrosis in the ZSF1 rat diabetic nephropathy model. Pharmacol. Res. Perspect. 5, e00354 (2017).","journal-title":"Pharmacol. Res. Perspect."},{"key":"284_CR96","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/nature12614","volume":"503","author":"EE Gerber","year":"2013","unstructured":"Gerber, E. E. et al. Integrin-modulating therapy prevents fibrosis and autoimmunity in mouse models of scleroderma. Nature 503, 126\u2013130 (2013).","journal-title":"Nature"},{"key":"284_CR97","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1042\/CS20171426","volume":"132","author":"GL Bagnato","year":"2018","unstructured":"Bagnato, G. L. et al. Dual \u03b1v\u03b23 and \u03b1v\u03b25 blockade attenuates fibrotic and vascular alterations in a murine model of systemic sclerosis. Clin. Sci. 132, 231\u2013242 (2018).","journal-title":"Clin. Sci."},{"key":"284_CR98","doi-asserted-by":"crossref","first-page":"208219","DOI":"10.1155\/2011\/208219","volume":"2011","author":"TR Katsumoto","year":"2011","unstructured":"Katsumoto, T. R., Violette, S. M. & Sheppard, D. Blocking TGF\u03b2 via inhibition of the \u03b1v\u03b26 integrin: a possible therapy for systemic sclerosis interstitial lung disease. Int. J. Rheumatol. 2011, 208219 (2011).","journal-title":"Int. J. Rheumatol."},{"key":"284_CR99","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41568-018-0038-z","volume":"18","author":"H Hamidi","year":"2018","unstructured":"Hamidi, H. & Ivaska, J. Every step of the way: integrins in cancer progression and metastasis. Nat. Rev. Cancer 18, 533\u2013548 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"284_CR100","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.tcb.2014.12.006","volume":"25","author":"L Seguin","year":"2015","unstructured":"Seguin, L., Desgrosellier, J. S., Weis, S. M. & Cheresh, D. A. Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance. Trends Cell Biol. 25, 234\u2013240 (2015).","journal-title":"Trends Cell Biol."},{"key":"284_CR101","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3390\/cancers9090116","volume":"9","author":"M Nieberler","year":"2017","unstructured":"Nieberler, M. et al. Exploring the role of RGD-recognizing integrins in cancer. Cancers 9, 116 (2017).","journal-title":"Cancers"},{"key":"284_CR102","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1172\/JCI200523183","volume":"115","author":"RC Bates","year":"2005","unstructured":"Bates, R. C. et al. Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J. Clin. Invest. 115, 339\u2013347 (2005).","journal-title":"J. Clin. Invest."},{"key":"284_CR103","doi-asserted-by":"crossref","first-page":"5889","DOI":"10.1158\/0008-5472.CAN-07-0245","volume":"67","author":"AN Elayadi","year":"2007","unstructured":"Elayadi, A. N. et al. A peptide selected by biopanning identifies the integrin alphavbeta6 as a prognostic biomarker for nonsmall cell lung cancer. Cancer Res. 67, 5889\u20135895 (2007).","journal-title":"Cancer Res."},{"key":"284_CR104","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/path.2168","volume":"212","author":"S Hazelbag","year":"2007","unstructured":"Hazelbag, S. et al. Overexpression of the alpha v beta 6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival. J. Pathol. 212, 316\u2013324 (2007).","journal-title":"J. Pathol."},{"key":"284_CR105","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.clon.2007.09.008","volume":"20","author":"ZY Zhang","year":"2008","unstructured":"Zhang, Z. Y. et al. Integrin alphavbeta6 acts as a prognostic indicator in gastric carcinoma. Clin. Oncol. 20, 61\u201366 (2008).","journal-title":"Clin. Oncol."},{"key":"284_CR106","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/annonc\/mdu474","volume":"26","author":"E \u00c9lez","year":"2015","unstructured":"\u00c9lez, E. et al. Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I\/II POSEIDON trial. Ann. Oncol. 26, 132\u2013140 (2015).","journal-title":"Ann. Oncol."},{"key":"284_CR107","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/bjc.2011.183","volume":"105","author":"S O\u2019Day","year":"2011","unstructured":"O\u2019Day, S. et al. CNTO 95 Investigators. A randomised, phase II study of intetumumab, an anti-\u03b1v-integrin mAb, alone and with dacarbazine in stage IV melanoma. Br. J. Cancer 105, 346\u2013352 (2011).","journal-title":"Br. J. Cancer"},{"key":"284_CR108","doi-asserted-by":"crossref","first-page":"136","DOI":"10.2967\/jnmt.117.203547","volume":"46","author":"N Keat","year":"2018","unstructured":"Keat, N. et al. A microdose PET study of the safety, immunogenicity, biodistribution, and radiation dosimetry of 18F-FB-A20FMDV2 for imaging the integrin \u03b1v\u03b26. J. Nucl. Med. Technol. 46, 136\u2013143 (2018).","journal-title":"J. Nucl. Med. Technol."},{"key":"284_CR109","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/path.5320","volume":"249","author":"CS Reader","year":"2019","unstructured":"Reader, C. S. et al. The integrin \u03b1v\u03b26 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. J. Pathol. 249, 332\u2013342 (2019).","journal-title":"J. Pathol."},{"key":"284_CR110","doi-asserted-by":"crossref","first-page":"dju169","DOI":"10.1093\/jnci\/dju169","volume":"106","author":"KM Moore","year":"2014","unstructured":"Moore, K. M. et al. Therapeutic targeting of integrin \u03b1v\u03b26 in breast cancer. J. Natl Cancer Inst. 106, dju169 (2014).","journal-title":"J. Natl Cancer Inst."},{"key":"284_CR111","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.7150\/thno.38702","volume":"10","author":"KM Moore","year":"2020","unstructured":"Moore, K. M. et al. Integrin \u03b1v\u03b26-specific therapy for pancreatic cancer developed from foot-and-mouth-disease virus. Theranostics 10, 2930\u20132942 (2020).","journal-title":"Theranostics"},{"key":"284_CR112","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen, D. S. & Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1\u201310 (2013).","journal-title":"Immunity"},{"key":"284_CR113","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252\u2013264 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"284_CR114","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13045-019-0779-5","volume":"12","author":"A Akinleye","year":"2019","unstructured":"Akinleye, A. & Rasool, Z. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J. Hematol. Oncol. 12, 92 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"284_CR115","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.3390\/cancers11091221","volume":"11","author":"NF Brown","year":"2019","unstructured":"Brown, N. F. & Marshall, J. F. Integrin-mediated TGF\u03b2 activation modulates the tumour microenvironment. Cancers 11, 1221 (2019).","journal-title":"Cancers"},{"key":"284_CR116","doi-asserted-by":"crossref","first-page":"20141","DOI":"10.1073\/pnas.1901931116","volume":"116","author":"A Vannini","year":"2019","unstructured":"Vannini, A. et al. \u03b1v\u03b23-integrin regulates PD-L1 expression and is involved in cancer immune evasion. Proc. Natl Acad. Sci. USA 116, 20141\u201320150 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"284_CR117","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2017.434","volume":"118","author":"RW Jenkins","year":"2018","unstructured":"Jenkins, R. W., Barbie, D. A. & Flaherty, K. T. Mechanisms of resistance to immune checkpoint inhibitors. Br. J. Cancer 118, 9\u201316 (2018).","journal-title":"Br. J. Cancer"},{"key":"284_CR118","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ccell.2020.12.001","volume":"39","author":"A Bagati","year":"2021","unstructured":"Bagati, A. et al. Integrin \u03b1v\u03b26-TGF\u03b2-SOX4 pathway drives immune evasion in triple-negative breast cancer. Cancer Cell 39, 54\u201367.e9 (2021).","journal-title":"Cancer Cell"},{"key":"284_CR119","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.122591","volume":"3","author":"N Takasaka","year":"2018","unstructured":"Takasaka, N. et al. Integrin \u03b1v\u03b28-expressing tumor cells evade host immunity by regulating TGF-\u03b2 activation in immune cells. JCI Insight 3, e122591 (2018).","journal-title":"JCI Insight"},{"key":"284_CR120","doi-asserted-by":"crossref","first-page":"109309","DOI":"10.1016\/j.celrep.2021.109309","volume":"36","author":"E Dodagatta-Marri","year":"2021","unstructured":"Dodagatta-Marri, E. et al. Integrin \u03b1v\u03b28 on T cells suppresses anti-tumor immunity in multiple models and is a promising target for tumor immunotherapy. Cell Rep. 36, 109309 (2021).","journal-title":"Cell Rep."},{"key":"284_CR121","unstructured":"Reszka-Blanco, N. et al. Inhibition of integrin \u03b1v\u03b28 enhances immune checkpoint induced anti-tumor immunity by acting across immunologic synapse in syngeneic models of breast cancer. Poster 1559. https:\/\/investor.morphictx.com\/static-files\/cc336336-fe88-4947-a8d9-5afbb5b4691c (2021)."},{"key":"284_CR122","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature25492","volume":"554","author":"D Tauriello","year":"2018","unstructured":"Tauriello, D. et al. TGF\u03b2 drives immune evasion in genetically reconstituted colon cancer metastasis. Nature 554, 538\u2013543 (2018).","journal-title":"Nature"},{"key":"284_CR123","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan, S. et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544\u2013548 (2018).","journal-title":"Nature"},{"key":"284_CR124","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2019-5010","author":"Y Hailemichael","year":"2019","unstructured":"Hailemichael, Y. et al. Potentiating immune checkpoint blockade therapeutic efficacy using a small molecule activator of integrin cell adhesion receptors [abstr.]. Cancer Res. https:\/\/doi.org\/10.1158\/1538-7445.AM2019-5010 (2019).","journal-title":"Cancer Res."},{"key":"284_CR125","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1126\/science.1070200","volume":"296","author":"JD Hood","year":"2002","unstructured":"Hood, J. D. et al. Tumor regression by targeted gene delivery to the neovasculature. Science 296, 2404\u20132407 (2002).","journal-title":"Science"},{"key":"284_CR126","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s13346-014-0210-2","volume":"5","author":"D Shan","year":"2015","unstructured":"Shan, D. et al. RGD-conjugated solid lipid nanoparticles inhibit adhesion and invasion of \u03b1v\u03b23 integrin-overexpressing breast cancer cells. Drug Deliv. Transl. Res. 5, 15\u201326 (2015).","journal-title":"Drug Deliv. Transl. Res."},{"key":"284_CR127","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/aps.2016.166","volume":"38","author":"T Zhang","year":"2017","unstructured":"Zhang, T. et al. Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice. Acta Pharmacol. Sin. 38, 835\u2013847 (2017).","journal-title":"Acta Pharmacol. Sin."},{"key":"284_CR128","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/1061186X.2018.1473409","volume":"27","author":"KR Gajbhiye","year":"2019","unstructured":"Gajbhiye, K. R., Gajbhiye, V., Siddiqui, I. A. & Gajbhiye, J. M. cRGD functionalised nanocarriers for targeted delivery of bioactives. J. Drug Target. 27, 111\u2013124 (2019).","journal-title":"J. Drug Target."},{"issue":"15_Suppl","key":"284_CR129","doi-asserted-by":"crossref","first-page":"TPS3144","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS3144","volume":"39","author":"A Patnaik","year":"2021","unstructured":"Patnaik, A. et al. A phase 1 study of SGN-B6A, an antibody-drug conjugate targeting integrin beta-6, in patients with advanced solid tumors (SGNB6A-001, Trial in Progress). J. Clin. Oncol. 39 (15_Suppl.), TPS3144 (2021).","journal-title":"J. Clin. Oncol."},{"key":"284_CR130","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1016\/j.jmb.2018.06.024","volume":"430","author":"MS Maginnis","year":"2018","unstructured":"Maginnis, M. S. Virus-receptor interactions: the key to cellular invasion. J. Mol. Biol. 430, 2590\u20132611 (2018).","journal-title":"J. Mol. Biol."},{"key":"284_CR131","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1007\/s00705-015-2579-8","volume":"160","author":"HA Hussein","year":"2015","unstructured":"Hussein, H. A. et al. Beyond RGD: virus interactions with integrins. Arch. Virol. 160, 2669\u20132681 (2015).","journal-title":"Arch. Virol."},{"key":"284_CR132","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.celrep.2019.11.020","volume":"30","author":"S Wang","year":"2020","unstructured":"Wang, S. et al. Integrin \u03b1v\u03b25 internalizes Zika virus during neural stem cells infection and provides a promising target for antiviral therapy. Cell Rep. 30, 969\u2013983.e4 (2020).","journal-title":"Cell Rep."},{"key":"284_CR133","doi-asserted-by":"crossref","first-page":"14644","DOI":"10.1073\/pnas.250299897","volume":"97","author":"CA Guerrero","year":"2000","unstructured":"Guerrero, C. A. et al. Integrin alpha(v)beta(3) mediates rotavirus cell entry. Proc. Natl Acad. Sci. USA 97, 14644\u201314649 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"284_CR134","doi-asserted-by":"crossref","first-page":"8003","DOI":"10.1073\/pnas.0807578106","volume":"106","author":"KL Schornberg","year":"2009","unstructured":"Schornberg, K. L. et al. Alpha5beta1-integrin controls ebolavirus entry by regulating endosomal cathepsins. Proc. Natl Acad. Sci. USA 106, 8003\u20138008 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"284_CR135","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15408","volume":"8","author":"A Kotecha","year":"2017","unstructured":"Kotecha, A. et al. Rules of engagement between \u03b1v\u03b26 integrin and foot-and-mouth disease virus. Nat. Commun. 8, 15408 (2017).","journal-title":"Nat. Commun."},{"key":"284_CR136","doi-asserted-by":"crossref","first-page":"104759","DOI":"10.1016\/j.antiviral.2020.104759","volume":"177","author":"CJ Sigrist","year":"2020","unstructured":"Sigrist, C. J., Bridge, A. & Le Mercier, P. A potential role for integrins in host cell entry by SARS-CoV-2. Antivir. Res. 177, 104759 (2020).","journal-title":"Antivir. Res."},{"key":"284_CR137","doi-asserted-by":"crossref","DOI":"10.3390\/v13020146","volume":"13","author":"L Makowski","year":"2021","unstructured":"Makowski, L., Olson-Sidford, W. & W-Weisel, J. Biological and clinical consequences of integrin binding via a rogue RGD motif in the SARS CoV-2 spike protein. Viruses 13, E146 (2021).","journal-title":"Viruses"},{"key":"284_CR138","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacbts.2020.10.003","volume":"6","author":"BJ Beddingfield","year":"2021","unstructured":"Beddingfield, B. J. et al. The integrin binding peptide, ATN-161, as a novel therapy for SARS-CoV-2 infection. JACC Basic Transl. Sci. 6, 1\u20138 (2021).","journal-title":"JACC Basic Transl. Sci."},{"key":"284_CR139","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.chembiol.2015.11.011","volume":"23","author":"RM Garbaccio","year":"2016","unstructured":"Garbaccio, R. M. & Parmee, E. R. The impact of chemical probes in drug discovery: a pharmaceutical industry perspective. Cell Chem. Biol. 23, 10\u201317 (2016).","journal-title":"Cell Chem. Biol."},{"key":"284_CR140","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","volume":"46","author":"CA Lipinski","year":"2001","unstructured":"Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46, 3\u201326 (2001).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"284_CR141","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","volume":"1","author":"CA Lipinski","year":"2004","unstructured":"Lipinski, C. A. Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov. Today Technol. 1, 337\u2013341 (2004).","journal-title":"Drug Discov. Today Technol."},{"key":"284_CR142","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1038\/nrd4128","volume":"12","author":"JG Cumming","year":"2013","unstructured":"Cumming, J. G., Davis, A. M., Muresan, S., Haeberlein, M. & Chen, H. Chemical predictive modelling to improve compound quality. Nat. Rev. Drug Discov. 12, 948\u2013962 (2013).","journal-title":"Nat. Rev. Drug Discov."},{"key":"284_CR143","doi-asserted-by":"crossref","first-page":"10005","DOI":"10.1021\/acs.jmedchem.8b01732","volume":"62","author":"M Egbert","year":"2019","unstructured":"Egbert, M., Whitty, A., Keser\u0171, G. M. & Vajda, S. Why some targets benefit from beyond rule of five drugs. J. Med. Chem. 62, 10005\u201310025 (2019).","journal-title":"J. Med. Chem."},{"key":"284_CR144","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1021\/acs.jmedchem.7b00717","volume":"61","author":"DA DeGoey","year":"2018","unstructured":"DeGoey, D. A., Chen, H. J., Cox, P. B. & Wendt, M. D. Beyond the Rule of 5: lessons learned from AbbVie\u2019s drugs and compound collection. J. Med. Chem. 61, 2636\u20132651 (2018).","journal-title":"J. Med. Chem."},{"key":"284_CR145","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","volume":"45","author":"DF Veber","year":"2002","unstructured":"Veber, D. F. et al. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 45, 2615\u20132623 (2002).","journal-title":"J. Med. Chem."},{"key":"284_CR146","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1161\/01.CIR.91.2.403","volume":"91","author":"NS Nicholson","year":"1995","unstructured":"Nicholson, N. S. et al. SC-54684A: an orally active inhibitor of platelet aggregation. Circulation 91, 403\u2013410 (1995).","journal-title":"Circulation"},{"key":"284_CR147","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/med.1007","volume":"21","author":"NS Nicholson","year":"2001","unstructured":"Nicholson, N. S. et al. Orbofiban: an orally active GPIIb\/IIIa platelet receptor antagonist. Med. Res. Rev. 21, 211\u2013226 (2001).","journal-title":"Med. Res. Rev."},{"key":"284_CR148","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11675","volume":"7","author":"RC Turaga","year":"2016","unstructured":"Turaga, R. C. et al. Rational design of a protein that binds integrin \u03b1v\u03b23 outside the ligand binding site. Nat. Commun. 7, 11675 (2016).","journal-title":"Nat. Commun."},{"key":"284_CR149","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1021\/acs.jmedchem.6b01711","volume":"60","author":"LM Miller","year":"2017","unstructured":"Miller, L. M., Pritchard, J. M., Macdonald, S., Jamieson, C. & Watson, A. Emergence of small-molecule non-RGD-mimetic inhibitors for RGD integrins. J. Med. Chem. 60, 3241\u20133251 (2017).","journal-title":"J. Med. Chem."},{"key":"284_CR150","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1002\/cmdc.201900359","volume":"14","author":"R Hatley","year":"2019","unstructured":"Hatley, R. et al. The design of potent, selective and drug-like RGD \u03b1v\u03b21 small-molecule inhibitors derived from non-RGD \u03b14\u03b21 antagonists. ChemMedChem 14, 1315\u20131320 (2019).","journal-title":"ChemMedChem"},{"key":"284_CR151","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1021\/acs.jmedchem.9b01869","volume":"63","author":"Y Zheng","year":"2020","unstructured":"Zheng, Y. & Leftheris, K. Insights into protein-ligand interactions in integrin complexes: advances in structure determinations. J. Med. Chem. 63, 5675\u20135696 (2020).","journal-title":"J. Med. Chem."},{"key":"284_CR152","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1126\/science.1064535","volume":"294","author":"JP Xiong","year":"2001","unstructured":"Xiong, J. P. et al. Crystal structure of the extracellular segment of integrin alpha Vbeta3. Science 294, 339\u2013345 (2001).","journal-title":"Science"},{"key":"284_CR153","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nature21035","volume":"542","author":"X Dong","year":"2017","unstructured":"Dong, X. et al. Force interacts with macromolecular structure in activation of TGF-\u03b2. Nature 542, 55\u201359 (2017).","journal-title":"Nature"},{"key":"284_CR154","doi-asserted-by":"crossref","first-page":"8417","DOI":"10.1021\/acs.jmedchem.8b00959","volume":"61","author":"PA Procopiou","year":"2018","unstructured":"Procopiou, P. A. et al. Discovery of (S)-3-(3-(3,5-dimethyl-1 H-pyrazol-1-yl)phenyl)-4-((R)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)butanoic acid, a nonpeptidic \u03b1v\u03b26 integrin inhibitor for the inhaled treatment of idiopathic pulmonary fibrosis. J. Med. Chem. 61, 8417\u20138443 (2018).","journal-title":"J. Med. Chem."},{"key":"284_CR155","doi-asserted-by":"crossref","first-page":"8001","DOI":"10.1039\/C5OB01237F","volume":"13","author":"JL Sorge","year":"2015","unstructured":"Sorge, J. L., Wagstaff, J. L., Rowe, M. L., Williamson, R. A. & Howard, M. J. Q2DSTD NMR deciphers epitope-mapping variability for peptide recognition of integrin \u03b1v\u03b26. Org. Biomol. Chem. 13, 8001\u20138007 (2015).","journal-title":"Org. Biomol. Chem."},{"key":"284_CR156","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1021\/ja044434w","volume":"127","author":"B Claasen","year":"2005","unstructured":"Claasen, B., Axmann, M., Meinecke, R. & Meyer, B. Direct observation of ligand binding to membrane proteins in living cells by a saturation transfer double difference (STDD) NMR spectroscopy method shows a significantly higher affinity of integrin alpha(IIb)beta3 in native platelets than in liposomes. J. Am. Chem. Soc. 127, 916\u2013919 (2005).","journal-title":"J. Am. Chem. Soc."},{"key":"284_CR157","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.bmc.2016.01.023","volume":"24","author":"F Vasile","year":"2016","unstructured":"Vasile, F. et al. Insight to the binding mode of triazole RGD-peptidomimetics to integrin-rich cancer cells by NMR and molecular modeling. Bioorg. Med. Chem. 24, 989\u2013994 (2016).","journal-title":"Bioorg. Med. Chem."},{"key":"284_CR158","doi-asserted-by":"crossref","first-page":"14645","DOI":"10.1002\/anie.201803250","volume":"57","author":"FS Di Leva","year":"2018","unstructured":"Di Leva, F. S. et al. From a helix to a small cycle: metadynamics-inspired \u03b1v\u03b26 integrin selective ligands. Angew. Chem. Int. Ed. Engl. 57, 14645\u201314649 (2018).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"284_CR159","doi-asserted-by":"crossref","unstructured":"Nanthakumar, C. B., Hatley, R. J. D. & Slack, R. J. in Anti-fibrotic Drug Discovery (eds Brenneman, J. & Iyer, M. R.) ch. 2, 37\u201375 (Royal Society of Chemistry, 2020).","DOI":"10.1039\/9781788015783-00037"},{"key":"284_CR160","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1021\/acs.jmedchem.8b01588","volume":"62","author":"F Reichart","year":"2019","unstructured":"Reichart, F. et al. Selective targeting of integrin \u03b1v\u03b28 by a highly active cyclic peptide. J. Med. Chem. 62, 2024\u20132037 (2019).","journal-title":"J. Med. Chem."},{"key":"284_CR161","doi-asserted-by":"crossref","first-page":"112719","DOI":"10.1016\/j.ejmech.2020.112719","volume":"208","author":"RA Lippa","year":"2020","unstructured":"Lippa, R. A. et al. Discovery of the first potent and selective \u03b1v\u03b25 integrin inhibitor based on an amide-containing core. Eur. J. Med. Chem. 208, 112719 (2020).","journal-title":"Eur. J. Med. Chem."},{"key":"284_CR162","doi-asserted-by":"crossref","first-page":"7543","DOI":"10.1021\/acs.jmedchem.9b00819","volume":"62","author":"TN Barrett","year":"2019","unstructured":"Barrett, T. N. et al. Profile of a highly selective quaternized pyrrolidine betaine \u03b1v\u03b26 integrin inhibitor-(3S)-3-(3-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl)-4-((1S and 1R,3R)-1-methyl-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-ium-1-yl)butanoate synthesized by stereoselective methylation. J. Med. Chem. 62, 7543\u20137556 (2019).","journal-title":"J. Med. Chem."},{"key":"284_CR163","doi-asserted-by":"crossref","first-page":"8796","DOI":"10.1021\/acs.jmedchem.9b00962","volume":"62","author":"NA Anderson","year":"2019","unstructured":"Anderson, N. A. et al. Discovery of an orally bioavailable pan \u03b1v integrin inhibitor for idiopathic pulmonary fibrosis. J. Med. Chem. 62, 8796\u20138808 (2019).","journal-title":"J. Med. Chem."},{"key":"284_CR164","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1016\/S0960-894X(01)00544-3","volume":"11","author":"WK Hagmann","year":"2001","unstructured":"Hagmann, W. K. et al. The discovery of sulfonylated dipeptides as potent VLA-4 antagonists. Bioorg. Med. Chem. Lett. 11, 2709\u20132713 (2001).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"284_CR165","doi-asserted-by":"crossref","first-page":"5457","DOI":"10.1021\/jm070252b","volume":"50","author":"S Choi","year":"2007","unstructured":"Choi, S. et al. Small molecule inhibitors of integrin alpha2beta1. J. Med. Chem. 50, 5457\u20135462 (2007).","journal-title":"J. Med. Chem."},{"key":"284_CR166","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1021\/acsmedchemlett.6b00196","volume":"7","author":"NI Reed","year":"2016","unstructured":"Reed, N. I. et al. Exploring N-arylsulfonyl-l-proline scaffold as a platform for potent and selective \u03b1v\u03b21 integrin inhibitors. ACS Med. Chem. Lett. 7, 902\u2013907 (2016).","journal-title":"ACS Med. Chem. Lett."},{"key":"284_CR167","volume":"7","author":"TG Kapp","year":"2017","unstructured":"Kapp, T. G. et al. A comprehensive evaluation of the activity and selectivity profile of ligands for RGD-binding integrins. Sci. Rep. 7, 39805 (2017).","journal-title":"Sci. Rep."},{"key":"284_CR168","unstructured":"Cha, J. et al. Amino acid compounds and methods of use. Patent WO2019173653 (2019)."},{"key":"284_CR169","unstructured":"Anderson, N. A. et al. Novel compounds. Patent WO2016046226 (2016)."},{"key":"284_CR170","unstructured":"Ruminski, P. G. & Griggs, D. W. Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists. Patent WO2017117538 (2017)."},{"key":"284_CR171","unstructured":"Thompson, J. Joint RSC CICAG-BMCS Meeting, Sygnature Discovery, BioCity, Nottingham, UK. Investigating the Chameleonic Properties of \u03b1V\u03b26 Integrin Antagonists for the Treatment of IPF. https:\/\/www.rsc.org\/images\/CICAG_Newsletter_Winter_2019-20_tcm18-252021.pdf (2019)"},{"key":"284_CR172","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1021\/jm100087s","volume":"53","author":"B Kuhn","year":"2010","unstructured":"Kuhn, B., Mohr, P. & Stahl, M. Intramolecular hydrogen bonding in medicinal chemistry. J. Med. Chem. 53, 2601\u20132611 (2010).","journal-title":"J. Med. Chem."},{"key":"284_CR173","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12931-020-01339-7","volume":"21","author":"TM Maher","year":"2020","unstructured":"Maher, T. M. et al. A positron emission tomography imaging study to confirm target engagement in the lungs of patients with idiopathic pulmonary fibrosis following a single dose of a novel inhaled \u03b1v\u03b26 integrin inhibitor. Respir. Res. 21, 75 (2020).","journal-title":"Respir. Res."},{"key":"284_CR174","unstructured":"Fierce Biotech. Biogen axes phase 2 study lung-scarring med due to safety concerns. https:\/\/www.fiercebiotech.com\/biotech\/biogen-axes-phase-2-study-lung-scarring-med-due-to-safety-concerns (2017)."},{"key":"284_CR175","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1111\/ajt.12467","volume":"13","author":"DJ Lo","year":"2013","unstructured":"Lo, D. J. et al. Inhibition of \u03b1v\u03b26 promotes acute renal allograft rejection in nonhuman primates. Am. J. Transplant. 13, 3085\u20133093 (2013).","journal-title":"Am. J. Transplant."},{"key":"284_CR176","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1161\/01.CIR.98.11.1085","volume":"98","author":"SH Tam","year":"1998","unstructured":"Tam, S. H., Sassoli, P. M., Jordan, R. E. & Nakada, M. T. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb\/IIIa and alpha(v)beta3 integrins. Circulation 98, 1085\u20131091 (1998).","journal-title":"Circulation"},{"key":"284_CR177","doi-asserted-by":"publisher","unstructured":"Raghu, G. et al. Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose-Escalation Study of BG00011 (Formerly STX-100) in Patients with Idiopathic Pulmonary Fibrosis (IPF). D14. ILD: Clinical Research. https:\/\/doi.org\/10.1164\/ajrccm-conference.2018.197.1_MeetingAbstracts.A7785 (2018).","DOI":"10.1164\/ajrccm-conference.2018.197.1_MeetingAbstracts.A7785"},{"key":"284_CR178","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1038\/onc.2012.460","volume":"32","author":"C Eberlein","year":"2013","unstructured":"Eberlein, C. et al. A human monoclonal antibody 264RAD targeting \u03b1v\u03b26 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivo. Oncogene 32, 4406\u20134416 (2013).","journal-title":"Oncogene"},{"key":"284_CR179","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/nrd3439-c1","volume":"10","author":"F Prinz","year":"2011","unstructured":"Prinz, F., Schlange, T. & Asadullah, K. Believe it or not: how much can we rely on published data on potential drug targets? Nat. Rev. Drug Discov. 10, 712 (2011).","journal-title":"Nat. Rev. Drug Discov."},{"key":"284_CR180","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1136\/thoraxjnl-2015-207429","volume":"71","author":"PF Mercer","year":"2016","unstructured":"Mercer, P. F. et al. Exploration of a potent PI3 kinase\/mTOR inhibitor as a novel anti-fibrotic agent in IPF. Thorax 71, 701\u2013711 (2016).","journal-title":"Thorax"},{"key":"284_CR181","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1002\/hep.30651","volume":"70","author":"HL Paish","year":"2019","unstructured":"Paish, H. L. et al. A bioreactor technology for modeling fibrosis in human and rodent precision-cut liver slices. Hepatology 70, 1377\u20131391 (2019).","journal-title":"Hepatology"},{"key":"284_CR182","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/ng.3314","volume":"47","author":"MR Nelson","year":"2015","unstructured":"Nelson, M. R. et al. The support of human genetic evidence for approved drug indications. Nat. Genet. 47, 856\u2013860 (2015).","journal-title":"Nat. Genet."},{"key":"284_CR183","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S2213-2600(17)30387-9","volume":"5","author":"RJ Allen","year":"2017","unstructured":"Allen, R. J. et al. Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study. Lancet Respir. Med. 5, 869\u2013880 (2017).","journal-title":"Lancet Respir. Med."},{"key":"284_CR184","first-page":"S91","volume":"74","author":"L Organ","year":"2021","unstructured":"Organ, L., Porte, J., John, A. & Jenkins, R. G. Investigating the role of AKAP13 in epithelial cells on TGF-\u03b2 activation. Thorax 74, S91 (2021).","journal-title":"Thorax"},{"key":"284_CR185","unstructured":"Hamilton R. J. (Ed. in Chief) Tarascon Pocket Pharmacopoeia (Jones & Bartlett Learning, 2020)"},{"key":"284_CR186","first-page":"PA5374","volume":"54","author":"K Kossen","year":"2019","unstructured":"Kossen, K. et al. IDL-2965: a selective, highly-potent, oral integrin antagonist for IPF. Eur. Respir. J. 54, PA5374 (2019).","journal-title":"Eur. Respir. J."},{"key":"284_CR187","doi-asserted-by":"crossref","unstructured":"Kossen, K. et al. IDL-2965: a selective, highly potent, clinical-stage integrin antagonist for the treatment of NASH. Poster. https:\/\/www.postersessiononline.eu\/173580348_eu\/congresos\/NAFLD2019\/aula\/-P05_17_NAFLD2019.pdf (2019).","DOI":"10.1183\/13993003.congress-2019.PA5374"},{"key":"284_CR188","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s10637-010-9388-4","volume":"29","author":"FM Chu","year":"2011","unstructured":"Chu, F. M. et al. A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human \u03b1(v) integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer. Invest. New Drugs 29, 674\u2013679 (2011).","journal-title":"Invest. New Drugs"},{"key":"284_CR189","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/annonc\/mds505","volume":"24","author":"A Heidenreich","year":"2013","unstructured":"Heidenreich, A. et al. A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human \u03b1\u03bd integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer. Ann. Oncol. 24, 329\u2013336 (2013).","journal-title":"Ann. Oncol."},{"key":"284_CR190","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00228-018-2435-3","volume":"74","author":"CH Maden","year":"2018","unstructured":"Maden, C. H. et al. Safety, tolerability and pharmacokinetics of GSK3008348, a novel integrin \u03b1v\u03b26 inhibitor, in healthy participants. Eur. J. Clin. Pharmacol. 74, 701\u2013709 (2018).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"284_CR191","first-page":"42","volume":"6","author":"MA Rosenthal","year":"2010","unstructured":"Rosenthal, M. A. et al. Evaluation of the safety, pharmacokinetics and treatment effects of an alpha(v)beta(3) integrin inhibitor on bone turnover and disease activity in men with hormone-refractory prostate cancer and bone metastases. Asia Pac. J. Clin. Oncol. 6, 42\u201348 (2010).","journal-title":"J. Clin. Oncol."},{"key":"284_CR192","unstructured":"Roche provides update on phase III studies of etrolizumab in people with moderately to severely active ulcerative colitis. https:\/\/www.roche.com\/investors\/updates\/inv-update-2020-08-10.htm (2021)."},{"key":"284_CR193","unstructured":"Vascular Pharma. VPI-2690B. http:\/\/www.vascularpharma.com\/science\/vpi-2690b (2021)."},{"key":"284_CR194","unstructured":"Oxurion NV \u2013 Expert Presentation of Positive Topline Data from a Phase 1 Study evaluating THR-687 for the treatment of DME, at Angiogenesis, Exudation, and Degeneration 2020 Conference. https:\/\/www.oxurion.com\/content\/oxurion-nv-expert-presentation-positive-topline-data-phase-1-study-evaluating-thr-687 (2020)."},{"key":"284_CR195","unstructured":"SciFluor Announces Positive Top-Line Results of Phase 1\/2 Study of SF0166 Eye Drops to Treat Wet Age-Related Macular Degeneration. https:\/\/www.businesswire.com\/news\/home\/20171218005625\/en\/SciFluor-Announces-Positive-Top-Line-Results-Phase-12 (2019)."},{"key":"284_CR196","first-page":"1944","volume":"61","author":"R Maturi","year":"2020","unstructured":"Maturi, R. et al. Safety and efficacy of risuteganib in intermediate non-exudative age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 61, 1944 (2020).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"284_CR197","doi-asserted-by":"crossref","first-page":"PA1298","DOI":"10.1183\/13993003.00889-2019","volume":"54","author":"S Turner","year":"2019","unstructured":"Turner, S. et al. Late Breaking Abstract - PK\/PD assessment of an oral, selective \u03b1V\u03b26\/\u03b1V\u03b21 integrin dual antagonist, PLN-74809, for the treatment of idiopathic pulmonary fibrosis. Eur. Respir. J. 54, PA1298 (2019).","journal-title":"Eur. Respir. J."},{"key":"284_CR198","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.tiv.2012.08.028","volume":"27","author":"DA Dalmas Wilk","year":"2013","unstructured":"Dalmas Wilk, D. A., Scicchitano, M. S. & Morel, D. In vitro investigation of integrin-receptor antagonist-induced vascular toxicity in the mouse. Toxicol. Vitr. 27, 272\u2013281 (2013).","journal-title":"Toxicol. Vitr."},{"key":"284_CR199","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1021\/bi00433a024","volume":"28","author":"J Hawiger","year":"1989","unstructured":"Hawiger, J., Kloczewiak, M., Bednarek, M. A. & Timmons, S. Platelet receptor recognition domains on the alpha chain of human fibrinogen: structure-function analysis. Biochemistry 28, 2909\u20132914 (1989).","journal-title":"Biochemistry"},{"key":"284_CR200","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1161\/01.CIR.103.2.201","volume":"103","author":"DP Chew","year":"2001","unstructured":"Chew, D. P., Bhatt, D. L., Sapp, S. & Topol, E. J. Increased mortality with oral platelet glycoprotein IIb\/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation 103, 201\u2013206 (2001).","journal-title":"Circulation"},{"key":"284_CR201","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/356063a0","volume":"356","author":"TA Yednock","year":"1992","unstructured":"Yednock, T. A. et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 356, 63\u201366 (1992).","journal-title":"Nature"},{"key":"284_CR202","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1053\/j.gastro.2018.11.035","volume":"156","author":"WJ Sandborn","year":"2019","unstructured":"Sandborn, W. J. et al. Efficacy and safety of abrilumab in a randomized, placebo-controlled trial for moderate-to-severe ulcerative colitis. Gastroenterology 156, 946\u2013957.e18 (2019).","journal-title":"Gastroenterology"},{"key":"284_CR203","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/bcp.14151","volume":"86","author":"H Fukase","year":"2020","unstructured":"Fukase, H., Kajioka, T., Oikawa, I., Ikeda, N. & Furuie, H. AJM300, a novel oral antagonist of \u03b14-integrin, sustains an increase in circulating lymphocytes: a randomised controlled trial in healthy male subjects. Br. J. Clin. Pharmacol. 86, 591\u2013600 (2020).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"284_CR204","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/apt.14631","volume":"47","author":"MT Tang","year":"2018","unstructured":"Tang, M. T. et al. Nonclinical and clinical pharmacology, pharmacokinestics and pharmacodynamics of etrolizumab, an anti-\u03b27 integrin therapy for inflammatory bowel disease. Aliment. Pharmacol. Ther. 47, 1440\u20131452 (2018).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"284_CR205","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(14)60661-9","volume":"384","author":"S Vermeire","year":"2014","unstructured":"Vermeire, S. et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet 384, 309\u2013318 (2014).","journal-title":"Lancet"},{"key":"284_CR206","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/embor.2009.276","volume":"11","author":"C Margadant","year":"2010","unstructured":"Margadant, C. & Sonnenberg, A. Integrin-TGF-beta crosstalk in fibrosis, cancer and wound healing. EMBO Rep. 11, 97\u2013105 (2010).","journal-title":"EMBO Rep."},{"key":"284_CR207","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1183\/09059180.00010909","volume":"17","author":"D Sheppard","year":"2008","unstructured":"Sheppard, D. The role of integrins in pulmonary fibrosis. Eur. Respir. Rev. 17, 157\u2013162 (2008).","journal-title":"Eur. Respir. Rev."},{"key":"284_CR208","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1083\/jcb.200109100","volume":"157","author":"D Mu","year":"2002","unstructured":"Mu, D. et al. The integrin alpha(v)beta8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-beta1. J. Cell Biol. 157, 493\u2013507 (2002).","journal-title":"J. Cell Biol."},{"key":"284_CR209","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.ejcb.2008.01.012","volume":"87","author":"PJ Wipff","year":"2008","unstructured":"Wipff, P. J. & Hinz, B. Integrins and the activation of latent transforming growth factor beta1 - an intimate relationship. Eur. J. Cell Biol. 87, 601\u2013615 (2008).","journal-title":"Eur. J. Cell Biol."},{"key":"284_CR210","doi-asserted-by":"crossref","first-page":"12384","DOI":"10.1074\/jbc.M208544200","volume":"278","author":"VJ Thannickal","year":"2003","unstructured":"Thannickal, V. J. et al. Myofibroblast differentiation by transforming growth factor-beta1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase. J. Biol. Chem. 278, 12384\u201312389 (2003).","journal-title":"J. Biol. Chem."}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41573-021-00284-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-021-00284-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-021-00284-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T18:49:22Z","timestamp":1733942962000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41573-021-00284-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,17]]},"references-count":210,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["284"],"URL":"https:\/\/doi.org\/10.1038\/s41573-021-00284-4","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.740832308.793588740","asserted-by":"object"}]},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,17]]},"assertion":[{"value":"26 July 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.J.D.H. and S.J.F.M. hold GSK shares and are applicants on GSK integrin patents. R.J.S. and J.A.R. hold GSK shares and are currently Galecto, Inc. employees and shareholders. R.G.J. reports grants from GlaxoSmithKline, grants and personal fees from Pliant Therapeutics, grants from Biogen, during the conduct of the study; personal fees from Galapagos, other from Galecto, personal fees and other from GlaxoSmithKline, personal fees and other from AstraZeneca, personal fees from Boehringer Ingelheim, personal fees from Pliant, personal fees from Bristol-Myers Squibb, personal fees from Chiesi, personal fees from Roche\/Promedior, personal fees and other from RedX, other from NuMedii, other from Nordic Biosciences, personal fees from Veracyte, personal fees from PatientMPower, personal fees from Resolution Therapeutics, personal fees from Vicore, outside the submitted work; he is supported by a National Institute of Health Research Professorship (NIHR ref: RP-2017-08-ST2-014). He is a trustee for Action for Pulmonary Fibrosis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}